Παρακολούθηση
Yasmin Mohseni
Yasmin Mohseni
A2 Biotherapeutics
Η διεύθυνση ηλεκτρονικού ταχυδρομείου έχει επαληθευτεί στον τομέα a2biotherapeutics.com
Τίτλος
Παρατίθεται από
Παρατίθεται από
Έτος
The future of regulatory T cell therapy: promises and challenges of implementing CAR technology
YR Mohseni, SL Tung, C Dudreuilh, RI Lechler, GO Fruhwirth, ...
Frontiers in immunology 11, 1608, 2020
852020
Treg cell therapy: How cell heterogeneity can make the difference
G Giganti, M Atif, Y Mohseni, D Mastronicola, N Grageda, GAM Povoleri, ...
European Journal of Immunology 51 (1), 39-55, 2021
692021
Chimeric antigen receptor‐modified human regulatory T cells that constitutively express IL‐10 maintain their phenotype and are potently suppressive
YR Mohseni, A Saleem, SL Tung, C Dudreuilh, C Lang, Q Peng, A Volpe, ...
European Journal of Immunology 51 (10), 2522-2530, 2021
272021
Spatiotemporal in vivo tracking of polyclonal human regulatory T cells (Tregs) reveals a role for innate immune cells in Treg transplant recruitment
J Jacob, S Nadkarni, A Volpe, Q Peng, SL Tung, RF Hannen, YR Mohseni, ...
Molecular Therapy-Methods & Clinical Development 20, 324-336, 2021
212021
Engineering regulatory T-cells for targeted transplantation tolerance using novel chimeric antigen receptors
Y Mohseni
King's College London, 2021
2021
POTENTIATING REGULATORY T CELLS USING CHIMERIC ANTIGEN RECEPTORS FOR TARGETED TRANSPLANTATION TOLERANCE
Y Mohseni, S Tung, A Volpe, G Fruhwirth, G Lombardi
TRANSPLANT INTERNATIONAL 32, 109-109, 2019
2019
Δεν είναι δυνατή η εκτέλεση της ενέργειας από το σύστημα αυτή τη στιγμή. Προσπαθήστε ξανά αργότερα.
Άρθρα 1–6